Sign Out
Pharmacology: THERAPEUTICAL ACTION: The immune system is formed by a complex of different cells that cooperatively receive and issue several signals aimed at target cells, thus regulating the defense mechanisms of the organism. The molecules responsible for the mediation of this interaction are proteins, peptides and other substances that in virtue of their activity are called immunomodulators.
The biological immunomodulating signals are formed by a group of molecules with specific properties. Many of them have been chemically and biologically characterized while others still call for discovery.
To the moment, INTERFERON has been the most widely used of this kind of molecules in clinical medicine and investigation.
The first clinical trials using INTERFERON took place in 1970, using the alpha type produced in leukocytes obtained from normal donors, and research increased as production was optimized and larger amounts of this protein were available.
Recombinant DNA technology constituted a turning point in the production of rHulFNα2. The development of this technology and that of monoclonal antibodies gave rise to a significant advance in the therapeutical use of this molecule, since great amounts of a highly purified preparation could be obtained.
rHulFNα2b-Sidus is produced by recombinant DNA techniques expressed in E.coli. The protein obtained is of M.W. 19,000 Dalton with a specific activity of 2 x 108 IU/mg of protein. It has an antiviral, antiproliferative and immunomodulating therapeutical activity.
